Yahoo Finance • 11 months ago

15 Small-Cap Stocks with High Potential

In this article, we will take a look at the 15 small-cap stocks with high potential. To skip our analysis of the latest trends, and market activity, you can go directly to see the 5 Small-Cap Stocks with High Potential. Nearly 9,500 stock... Full story

Yahoo Finance • last year

Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies

Olema Oncology Palazestrant (OP-1250) in combination with the CDK 4/6 inhibitors, ribociclib and palbociclib, demonstrated no significant drug-drug interaction, no dose-limiting toxicities and a tolerability profile consistent with the FD... Full story

Yahoo Finance • last year

Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)

Olema Oncology Presentations detailing initial Phase 1b clinical data for palazestrant in combination with ribociclib, a Poster Spotlight Session on Phase 2 clinical data for palazestrant in combination with palbociclib, and the OPERA-01... Full story

Yahoo Finance • 2 years ago

Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update

Initiation of first pivotal Phase 3 monotherapy clinical trial of OP-1250 in second- and third-line metastatic breast cancer planned for the second half of 2023Interim Phase 2 clinical results of OP-1250 in combination with palbociclib to... Full story

Yahoo Finance • 2 years ago

Olema Oncology to Present at 41st Annual J.P. Morgan Healthcare Conference

Olema Oncology SAN FRANCISCO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA) today announced that Sean Bohen, M.D., President and Chief Executive Officer, will present at the 41st A... Full story

Yahoo Finance • 2 years ago

We Think Olema Pharmaceuticals (NASDAQ:OLMA) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But the har... Full story

Yahoo Finance • 2 years ago

Olema Oncology to Present at Upcoming Investor Conferences in November

SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercializat... Full story

Yahoo Finance • 2 years ago

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Pharmaceuticals, Inc. SAN FRANCISCO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, deve... Full story

Yahoo Finance • 2 years ago

Olema Pharmaceuticals (NASDAQ:OLMA) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose money for years before finding success with... Full story